Efavirenz
Composition
The formulation contains Efavirenz 600 mg with lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate as the active ingredient.
Indications
Indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents.
Side effects
Common side effects include dizziness, insomnia, rash, nausea, fatigue, and neuropsychiatric symptoms such as depression and vivid dreams.
Precautions
Monitor for neuropsychiatric symptoms, liver function, and lipid levels; use with caution in patients with a history of mental illness, liver disease, or those taking other hepatotoxic drugs; avoid in pregnancy due to potential teratogenic effects.
Contraindications
Significant drug interactions with CYP inducers/inhibitors
Dosage and administration
600 mg once daily, on an empty stomach at bedtime
Countries
Brazil, Thailand, South Africa
Available Forms
Capsules, tablets
Manufacturing Services
Third Party Manufacturing Company WHO, GMP, EUGMP, USFDA, In India | Contract Manufacturing Organization (CMO) WHO, GMP, EUGMP, USFDA Services in India, Mumbai, Navi Mumbai| Contract Development and Manufacturing Organization (CDMO) WHO, GMP, EUGMP, USFDA - Services in India | Pharmaceutical Contract Manufacturing Company WHO, GMP, EUGMP, USFDA in Navi Mumbai, India | Top Pharmaceutical Product Exporters, Suppliers, Distributer WHO, GMP, EUGMP, USFDA in Mumbai